Gene · 5300
Papers3,752
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
801 to 820 of 3,752
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DEGnext: classification of differentially expressed genes from RNA-seq data using a convolutional neural network with transfer learning. | BMC Bioinformatics | 2022 | 34991439 | PubTator, text mining | PubMed |
| Orchestrating serine/threonine phosphorylation and elucidating downstream effects by short linear motifs. | Biochem J | 2022 | 34989786 | PubTator, text mining | PubMed |
| Mammalian Ssu72 phosphatase preferentially considers tissue-specific actively transcribed gene expression by regulating RNA Pol II transcription. | Theranostics | 2022 | 34987641 | PubTator, text mining | PubMed |
| circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. | Mol Cancer | 2022 | 34980129 | PubTator, text mining | PubMed |
| PDBcor: An automated correlation extraction calculator for multi-state protein structures. | Structure | 2022 | 34963060 | PubTator, text mining | PubMed |
| Therapeutic targeting of "undruggable" MYC. | EBioMedicine | 2022 | 34942444 | PubTator, text mining | PubMed |
| Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4. | Mol Cancer Res | 2022 | 34933912 | PubTator, text mining | PubMed |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 directly binds and stabilizes Nrf2 in breast cancer. | FASEB J | 2022 | 34918396 | PubTator, text mining | PubMed |
| Nephrotoxicity evaluation of 3-monochloropropane-1,2-diol exposure in Sprague-Dawley rats using data-independent acquisition-based quantitative proteomics analysis. | Toxicol Lett | 2022 | 34915118 | PubTator, text mining | PubMed |
| Targeting intracellular protein-protein interactions with macrocyclic peptides. | Trends Pharmacol Sci | 2022 | 34911657 | PubTator, text mining | PubMed |
| New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy. | J Enzyme Inhib Med Chem | 2022 | 34894990 | PubTator, text mining | PubMed |
| Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy. | Cancer Epidemiol Biomarkers Prev | 2022 | 34862210 | PubTator, text mining | PubMed |
| Expanding role of PI5P4Ks in cancer: A promising druggable target. | FEBS Lett | 2022 | 34822164 | PubTator, text mining | PubMed |
| Anticancer properties and pharmaceutical applications of ginsenoside compound K: A review. | Chem Biol Drug Des | 2022 | 34793617 | PubTator, text mining | PubMed |
| Proteomic Signatures of Human Visceral and Subcutaneous Adipocytes. | J Clin Endocrinol Metab | 2022 | 34669916 | PubTator, text mining | PubMed |
| Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. | Mol Neurobiol | 2022 | 34655056 | PubTator, text mining | PubMed |
| Accumulation of amyloid beta (Aβ) and amyloid precursor protein (APP) in tumors formed by a mouse xenograft model of inflammatory breast cancer. | FEBS Open Bio | 2022 | 34592066 | PubTator, text mining | PubMed |
Selective 1 Hα NMR Methods Reveal Functionally Relevant Proline cis/trans Isomers in Intrinsically Disordered Proteins: Characterization of Minor Forms, Effects of Phosphorylation, and Occurrence in Proteome. | Angew Chem Int Ed Engl | 2022 | 34585830 | PubTator, text mining | PubMed |
| The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. | Nat Rev Clin Oncol | 2022 | 34508258 | PubTator, text mining | PubMed |
| Molecular docking, 3D-QASR and molecular dynamics simulations of thiazoles Pin1 inhibitors. | J Biomol Struct Dyn | 2022 | 34499020 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5300/papers?page=41